AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca's Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board's Determination that Activist Group's Nominations Are Invalid
AIM ImmunoTech Provides Update Regarding Annual Meeting
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
 1   2     3    4   5   6   7   8 
 <<   <   >   >>